NM_002483.7(CEACAM6):c.50A>T (p.Glu17Val) AND not specified

Germline classification:: Uncertain significance (1 submission)
Last evaluated:: Jan 31, 2024
Review status:: 1 star out of maximum of 4 stars
criteria provided, single submitter

Somatic classification of clinical impact:: None
Review status:: (0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided

Somatic classification of oncogenicity:: None
Review status:: (0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided

Record status:: current
Accession:: RCV004431174.1

Allele description [Variation Report for NM_002483.7(CEACAM6):c.50A>T (p.Glu17Val)]

NM_002483.7(CEACAM6):c.50A>T (p.Glu17Val)

Gene:

CEACAM6:CEA cell adhesion molecule 6 [Gene - OMIM - HGNC]

Variant type:

single nucleotide variant

Cytogenetic location:

19q13.2

Genomic location:

Preferred name:

NM_002483.7(CEACAM6):c.50A>T (p.Glu17Val)

HGVS:

NC_000019.10:g.41755688A>T
NM_002483.7:c.50A>TMANE SELECT
NP_002474.4:p.Glu17Val
NC_000019.9:g.42259596A>T
NM_002483.4:c.50A>T

Protein change:

E17V

Molecular consequence:

NM_002483.7:c.50A>T - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Synonyms:: AllHighlyPenetrant
Identifiers:: MedGen: CN169374

Recent activity

Clear Turn Off Turn On

phosphoserine phosphatase isoform X2 [Homo sapiens]
phosphoserine phosphatase isoform X2 [Homo sapiens]
gi|2462615459|ref|XP_054214679.1|

Protein
PREDICTED: Rattus norvegicus ninein (Nin), transcript variant X3, mRNA
PREDICTED: Rattus norvegicus ninein (Nin), transcript variant X3, mRNA
gi|2678950725|ref|XM_017594089.3|

Nucleotide
Homo sapiens interleukin 15 (IL15), transcript variant 2, mRNA
Homo sapiens interleukin 15 (IL15), transcript variant 2, mRNA
gi|323098328|ref|NM_172175.2|

Nucleotide
Lowry-Wood syndrome
Lowry-Wood syndrome

MedGen
C0796021[conceptid] (1)
MedGen

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

Help

Submission Accession	Submitter	Review Status (Assertion method)	Clinical Significance (Last evaluated)	Origin	Method	Citations
SCV004920773	Ambry Genetics	criteria provided, single submitter (Ambry Variant Classification Scheme 2023)	Uncertain significance (Jan 31, 2024)	germline	clinical testing	Citation Link

Submission Accession

Submitter

Review Status
(Assertion method)

Clinical Significance
(Last evaluated)

Origin

Method

Citations

SCV004920773

Ambry Genetics

criteria provided, single submitter

(Ambry Variant Classification Scheme 2023)

Uncertain significance
(Jan 31, 2024)

germline

clinical testing

Citation Link

Help

Summary from all submissions

Ethnicity	Origin	Affected	Individuals	Families	Chromosomes tested	Number Tested	Family history	Method
not provided	germline	unknown	not provided	not provided	not provided	not provided	not provided	clinical testing

Details of each submission

From Ambry Genetics, SCV004920773.1

#	Ethnicity	Individuals	Chromosomes Tested	Family History	Method	Citations
1	not provided	not provided	not provided	not provided	clinical testing	not provided

Description

The c.50A>T (p.E17V) alteration is located in exon 1 (coding exon 1) of the CEACAM6 gene. This alteration results from a A to T substitution at nucleotide position 50, causing the glutamic acid (E) at amino acid position 17 to be replaced by a valine (V). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear.

#	Sample				Method		Observation
#	Origin	Affected	Number tested	Tissue	Purpose	Method	Individuals	Allele frequency	Families	Co-occurrences
1	germline	unknown	not provided	not provided	not provided		not provided	not provided	not provided	not provided

Last Updated: May 7, 2024

ClinVar

Relating variation to medicine